OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Letters is 60. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
CircRNA in cancer: Fundamental mechanism and clinical potential	271
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs	268
Clinical practice guidelines for the management of adult diffuse gliomas	226
Resveratrol for cancer therapy: Challenges and future perspectives	212
Incidence, mortality, survival, risk factor and screening of colorectal cancer: A comparison among China, Europe, and northern America	190
Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis	185
Regulation of Nuclear Factor-KappaB (NF-κB) signaling pathway by non-coding RNAs in cancer: Inhibiting or promoting carcinogenesis?	177
Long non-coding RNAs in the doxorubicin resistance of cancer cells	131
Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?	128
Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer	120
Sonodynamic therapy-derived multimodal synergistic cancer therapy	120
HPV post-infection microenvironment and cervical cancer	118
Gut microbiota-derived short-chain fatty acids and colorectal cancer: Ready for clinical translation?	117
Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics	112
ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway	111
Metabolic adaptation in hypoxia and cancer	106
APOBEC: A molecular driver in cervical cancer pathogenesis	102
LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack	101
Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity	100
Autophagy and cancer drug resistance in dialogue: Pre-clinical and clinical evidence	100
LncRNAs in cancer: Regulatory and therapeutic implications	99
The oncogenic and clinical implications of lactate induced immunosuppression in the tumour microenvironment	97
Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell	96
CircRNAs in lung cancer - Biogenesis, function and clinical implication	96
Translation of noncoding RNAs and cancer	94

METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF-κB to promote the malignant progression of IDH-wildtype glioma	94
Phospholipase A2 superfamily in cancer	93
Epstein–Barr virus-associated gastric cancer: A distinct subtype	91
Wnt signaling pathway in cancer immunotherapy	91
Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids	90
Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy	86
KLF2 inhibits cancer cell migration and invasion by regulating ferroptosis through GPX4 in clear cell renal cell carcinoma	85
Exosomal circ_0030167 derived from BM-MSCs inhibits the invasion, migration, proliferation and stemness of pancreatic cancer cells by sponging miR-338-5p and targeting the Wif1/Wnt8/β-catenin axis	81
M2 macrophage-derived exosomes promote lung adenocarcinoma progression by delivering miR-942	81
Exosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated pancreatic cancer cell proliferation and metastasis	80
Exosome-mediated delivery of RNA and DNA for gene therapy	80
Fibronectin regulates anoikis resistance via cell aggregate formation	76
Recent advances in strategies for overcoming hypoxia in photodynamic therapy of cancer	76
The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy	74
Targeting neutrophil extracellular traps with thrombomodulin prevents pancreatic cancer metastasis	73
NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma	72
Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer	71
Cancer screening in China: The current status, challenges, and suggestions	71
Reality CHEK: Understanding the biology and clinical potential of CHK1	69
Metabolism and function of polyamines in cancer progression	66
Photodynamic therapy induces human esophageal carcinoma cell pyroptosis by targeting the PKM2/caspase-8/caspase-3/GSDME axis	65
Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope	65
Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance	65
Non-matrigel scaffolds for organoid cultures	65
A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer	64
Mesenchymal stem cell-derived exosome: A tumor regulator and carrier for targeted tumor therapy	64
Hippo pathway: Regulation, deregulation and potential therapeutic targets in cancer	64
SLC7A11/ xCT is a target of miR-5096 and its restoration partially rescues miR-5096-mediated ferroptosis and anti-tumor effects in human breast cancer cells	64
Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer	63
The treatment landscape of metastatic prostate cancer	62
PMN-MDSCs accumulation induced by CXCL1 promotes CD8+ T cells exhaustion in gastric cancer	62
Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer	62
CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer	62
Sonodynamic therapy: Rapid progress and new opportunities for non-invasive tumor cell killing with sound	62
SIRT3 inhibits gallbladder cancer by induction of AKT-dependent ferroptosis and blockade of epithelial-mesenchymal transition	62